CD80 and neoplasm: They demonstrated that in settings where only the trans-PD-L1/CD80 interaction can exist (implantation of CD274KO tumor cells in CD80KO mice), blocking this interaction, without interfering with the PD-1/PD-L1 interaction, is sufficient to increase anti-tumor immunity.